Interpace Biosciences Receivables

The latest receivables for IDXG is $5.9M as of March 2026. That compares with $8.8M in the prior-year period — down 32.4% year over year. Investors often review this figure alongside Interpace Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, IDXG's receivables moved from $8.8M to $5.9M — a 32.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Interpace Biosciences's operating scale or balance-sheet position.

A receivables figure of $5.9M for IDXG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IDXG's receivables ($5.9M), review year-over-year change from $8.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.